Latest Content

Experts discuss how better hospice and home care reimbursement can help patients receive compassionate end-of-life care at home.

Get the facts on stage 1 multiple myeloma, including why your doctor may recommend active surveillance and what the latest treatment options are.

The addition of postsurgical Verzenio to endocrine therapy provided a benefit in HR–positive, HER2-negative breast cancer.

Learn what stage 2 ovarian cancer means, how it’s diagnosed, treatment options like surgery and chemotherapy, and key questions to ask your oncologist.

Shopping for prostheses reminded me of being in a very popular old toy store.

Dr. Matthew Matasar discusses why stem cell transplant is still a standard, life-saving option in blood cancers and how CAR-T cell therapy is changing treatment decisions.

In PD-1/PD-L1-pretreated recurrent/metastatic head and neck squamous cell carcinoma buparlisib and paclitaxel was not associated with a survival improvement.

In patients with operable, newly diagnosed brain metastases, GammaTile was associated with reduction in the risk of tumor recurrence or death.

Breast cancer survivors highlighted guidance and encouragement they received when first diagnosed, offering reassurance for those who are newly diagnosed.

Camrelizumab plus famitinib extended progression-free survival to 11.1 months versus 7.5 months with chemotherapy in recurrent or metastatic cervical cancer.

Alecensa achieved a 98.4% 4-year overall survival rate versus 92.4% with chemotherapy in resected ALK-positive early-stage lung cancer.

Trodelvy plus Keytruda may maintain quality of life and slow physical decline in metastatic triple-negative breast cancer.

Antibody-drug conjugate treatment rates increased 3.7-fold from 2021 to 2023 for patients with metastatic breast cancer.